A Phase 2 clinical trial is underway to evaluate a treatment specifically targeting the MET exon 14 skipping mutations in patients with locally advanced or metastatic NSCLC, including those with sarcomatoid histology. This evidence concerns the gene MET and non-small cell lung carcinoma.